Firefly Neuroscience Partners with Neurology Consultants
Firefly Neuroscience, Inc. (“Firefly,” “we,” or the “Company”) (NASDAQ: AIFF), an innovative Artificial Intelligence (“AI”) technology firm dedicated to developing cutting-edge neuroscientific solutions aimed at improving brain health for individuals with mental illnesses and neurological disorders, has announced a strategic partnership with Neurology Consultants of Dallas (“NCD”). This collaboration aims to enhance early detection and disease management for patients experiencing cognitive decline. NCD will integrate Firefly’s Brain Network Analytics (“BNA”) technology into its patient workflow and will conduct clinical studies to identify biomarkers that can predict the onset of dementia, potentially optimizing care pathways for patients.
Goals of the Collaboration
NCD has been a leader in neurological care since the 1970s, offering both inpatient and outpatient services. “NCD's commitment to enhancing patient outcomes makes them an ideal partner for Firefly,” stated Jon Olsen, Firefly’s CEO. “We are eager to update our BNA technology with real-world patient use cases and feedback, allowing us to better assist those affected by cognitive decline and other neurological disorders throughout the U.S.”
Advantages of Integrating BNA Technology
According to Dr. Puneet Gupta, NCD's VP of Health Innovation Strategy and Ventures, “The incorporation of Firefly's BNA technology underscores the clinical value of this platform, offering diagnostic insights and trending analyses of cognitive health for conditions like Alzheimer's disease, Parkinson’s disease, epilepsy, multiple sclerosis, concussions, and general aging. By integrating BNA into our ongoing cognitive assessments, we can achieve a more thorough understanding of our patients' brain function and cognitive health over time.”
Improving Patient Care
Establishing a baseline for each patient enables healthcare providers to monitor cognitive changes more accurately, which promotes early detection and effective management of cognitive decline. The integration of BNA technology is expected to significantly enhance neurology testing for millions of patients in the U.S., encouraging the widespread adoption of advanced diagnostic tools.
Dedication to Patient Outcomes
Dr. Anna Tseng, NCD’s Chief Development Officer, noted, “Recently, NCD was selected to participate in the Centers for Medicare and Medicaid Services’ GUIDE Model, which aims to substantially improve the quality of life for individuals with dementia. We believe our partnership with Firefly will bolster our capacity to assess the level of cognitive impairment in patients involved in the program, allowing us to manage their care based on the stage of dementia. This aligns with our ongoing commitment to advancing patient care through innovative technology.”
About Firefly Neuroscience
Firefly (NASDAQ: AIFF) is an AI technology company focused on developing groundbreaking neuroscientific solutions that enhance brain health outcomes for patients with mental illnesses and neurological disorders. The company’s FDA-510(k) cleared Brain Network Analytics (BNA) platform is transforming diagnostic and treatment approaches for conditions such as depression, dementia, anxiety disorders, concussions, and ADHD.
Investment and Development Efforts
Over the last 15 years, Firefly has invested around $60 million into the development of its BNA platform, which includes building a comprehensive database of brain wave tests, securing patent protections, and achieving FDA approval. The Company is now commercially launching the BNA platform, targeting pharmaceutical companies involved in drug research and clinical trials, as well as medical practitioners for clinical applications.
Advanced Technology
The BNA platform is a software as a medical solution (SAMS) developed using artificial intelligence and machine learning, utilizing Firefly’s extensive proprietary database of standardized, high-definition longitudinal electroencephalograms (EEGs) from over 17,000 patients. This platform, combined with an FDA-cleared EEG system, offers clinicians detailed insights into brain function and cognition, thereby improving the accuracy of diagnosing mental illnesses and cognitive disorders.
About Neurology Consultants of Dallas
Neurology Consultants of Dallas (NCD) is a prominent physician-owned and physician-led practice committed to delivering exceptional neurological care to the community. With a holistic approach to treatment, NCD provides state-of-the-art services for both adult and pediatric patients, across inpatient and outpatient settings.
Commitment to Quality Care
NCD offers a wide range of services, including expertise in various specialties, advanced diagnostics and imaging, clinical research, and neurorehabilitation. The practice actively collaborates with startups and established healthcare companies to refine products, shape future therapies, and optimize workflows, driving innovation that significantly impacts the healthcare landscape.
Frequently Asked Questions
What is the purpose of the partnership between Firefly and NCD?
The partnership is designed to enhance early detection and disease management for patients experiencing cognitive decline through the use of Firefly's BNA technology.
How does BNA technology benefit patients?
BNA technology aids in identifying biomarkers, which allows for improved tracking and management of cognitive decline over time.
What are the primary conditions addressed by BNA technology?
BNA technology targets conditions such as Alzheimer's disease, Parkinson’s disease, epilepsy, multiple sclerosis, concussions, and cognitive decline related to aging.
How long has Firefly been developing its BNA technology?
Firefly has dedicated approximately $60 million to the development of its BNA platform over the past 15 years.
What is NCD’s approach to patient care?
NCD emphasizes a holistic treatment philosophy, combining the latest research and technology with compassionate, personalized care for patients.
